TL;DR: The Centers for Medicare & Medicaid Services modified NCD 46 governing HIV testing for prognosis and monitoring, with an effective date of January 9, 2026. Here's what billing teams need to know.
This update to the CMS HIV testing coverage policy under NCD 46 Medicare clarifies the indications, limitations, and testing frequency standards for HIV plasma RNA quantification. No specific CPT or HCPCS codes are listed in the policy document itself — the policy directs you to quarterly Covered Code Lists published separately. If your practice bills for HIV viral load testing or CD4+ T cell monitoring, this policy governs your Medicare reimbursement and medical necessity documentation requirements.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring) |
| Policy Code | NCD 46 |
| Change Type | Modified |
| Effective Date | 2026-01-09 |
| Impact Level | Medium — affects any practice billing Medicare for HIV viral load or RNA quantification testing |
| Specialties Affected | Infectious disease, internal medicine, primary care, clinical laboratory |
| Key Action | Audit documentation to confirm HIV viral load testing frequency aligns with current CDC antiretroviral guidelines and that baseline specimens are documented correctly |
CMS HIV Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 46 is the National Coverage Determination governing CMS HIV testing coverage policy for prognostic and monitoring purposes. It does not cover diagnostic HIV testing — that's a different category entirely. This policy covers HIV plasma RNA quantification, which measures circulating viral RNA to assess disease progression risk and antiretroviral therapy (ART) response.
Three situations establish medical necessity under this coverage policy:
First, any patient with confirmed HIV infection qualifies for a plasma HIV RNA baseline level. The confirmation of HIV infection is what triggers coverage — not a suspicion or a risk assessment.
Second, regular periodic measurement of plasma HIV RNA is covered to assess disease progression risk and to guide decisions about when to start or adjust antiretroviral regimens. The word "periodic" is doing a lot of work here. CMS ties acceptable frequency directly to current CDC guidelines on antiretroviral use in adults, adolescents, and pediatric patients. If your testing frequency doesn't match CDC guidance, you have a denial risk.
Third, a baseline HIV quantification is covered in specific clinical situations where HIV infection risk is significant and therapy is likely. This covers two scenarios: persistent borderline or equivocal serologic reactivity in an at-risk individual, and signs of acute retroviral syndrome — fever, malaise, lymphadenopathy, and rash in an at-risk individual. These are narrow indications. Document them precisely.
One thing worth noting about prior authorization: NCD 46 does not list a prior authorization requirement for this testing. But that doesn't mean your Medicare Administrative Contractor won't have additional local requirements. Check your MAC's local coverage determination before assuming prior auth is off the table.
CMS HIV Testing Exclusions and Non-Covered Indications
The biggest exclusion in this policy is also the most commonly misapplied one: HIV RNA quantification is not covered as a diagnostic test.
That distinction matters. Viral load testing is covered when you're managing a confirmed infection — monitoring disease progression, guiding ART decisions, establishing a baseline. It is not a substitute for serologic testing to diagnose HIV in the first place. Bill it as a diagnostic tool and you're looking at a claim denial.
CMS also flags that different assays produce different absolute HIV copy numbers. If a patient's testing switches between assay methods — say, from one lab to another — the clinical record needs to reflect that a new baseline was established. This isn't a billing technicality; it's a documentation requirement that directly supports medical necessity on a claim.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Plasma HIV RNA baseline — confirmed HIV infection | Covered | See quarterly Covered Code Lists | Any confirmed HIV patient qualifies |
| Periodic HIV RNA measurement for disease progression monitoring | Covered | See quarterly Covered Code Lists | Frequency must align with current CDC ART guidelines |
| Periodic HIV RNA measurement to guide ART initiation or modification | Covered | See quarterly Covered Code Lists | Document clinical rationale for regimen change |
| Baseline HIV RNA — equivocal serologic reactivity in at-risk individual | Covered | See quarterly Covered Code Lists | Document at-risk status and equivocal serology result |
| Baseline HIV RNA — acute retroviral syndrome signs in at-risk individual | Covered | See quarterly Covered Code Lists | Document fever, malaise, lymphadenopathy, and/or rash |
| HIV RNA quantification as a diagnostic test | Not Covered | N/A | Diagnostic use is explicitly excluded; use serologic testing for diagnosis |
| HIV RNA testing exceeding CDC-recommended frequency | Not Covered | N/A | Frequency must be consistent with current CDC guidelines |
CMS HIV Testing Billing Guidelines and Action Items 2026
These are your concrete steps before and after the January 9, 2026 effective date.
1. Pull the current CDC antiretroviral guidelines and map your testing frequency against them.
CMS uses CDC guidance as the benchmark for what counts as "regular, periodic" testing. If your standing orders or lab requisition templates use a frequency that's out of sync with the current CDC recommendations for adults, adolescents, or pediatrics, you're exposed. The CDC updates these guidelines — don't assume last year's version is still current.
2. Audit your baseline documentation.
NCD 46 is specific: for an accurate HIV RNA baseline, two specimens within a two-week window are appropriate. Your documentation needs to show that baseline specimens were collected in that window. If your records just show a single baseline draw with no note about the second specimen, that's a gap. Fix it in your intake workflow now, before January 9, 2026.
3. Document the clinical indication at the time of every order — not retroactively.
Medical necessity documentation for HIV viral load testing must connect the order to one of the covered indications. "HIV monitoring" alone isn't enough. The note should say whether this is a baseline draw, a periodic progression check, or a response-to-therapy measure. If it's the acute retroviral syndrome indication, list the specific symptoms — fever, malaise, lymphadenopathy, rash.
4. Track assay method changes and re-baseline when the method changes.
If your lab switches assay platforms, or a patient switches labs, the HIV RNA billing guidelines require re-establishing a baseline. That re-baseline is a covered service — but only if you document why the method changed. Build this into your lab change management process.
5. Check your quarterly Covered Code Lists for the applicable CPT codes.
NCD 46 does not list specific CPT or HCPCS codes in the policy body. CMS publishes Covered Code Lists quarterly. Pull the current list from the CMS Regulations and Guidance page and confirm your charge capture reflects the active codes. If your billing team is working off an outdated code list, you'll have claim denials that have nothing to do with clinical documentation.
6. Confirm there's no MAC-level local coverage determination layered on top.
NCD 46 is a national policy, but your Medicare Administrative Contractor can add restrictions. Search your MAC's LCD database for any HIV testing local coverage determination that narrows frequency, adds diagnosis code requirements, or flags additional prior authorization requirements for your region. If you're unsure, talk to your compliance officer before the January 9, 2026 effective date.
7. Do not bill HIV RNA quantification to Medicare as a diagnostic tool.
This bears repeating because it's the most common misapplication of this policy. If a patient comes in with unknown HIV status and you order a viral load, that's a diagnostic use — and it's not covered under NCD 46. The covered path for diagnosis is serologic testing. HIV viral load testing billing under this policy begins after confirmed infection is established.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for HIV Testing Under NCD 46
Covered Codes
NCD 46 does not list specific CPT or HCPCS codes directly in the policy document. CMS publishes the applicable codes in quarterly Covered Code Lists. You must pull those lists directly from CMS to confirm which codes are active and covered under this policy.
To find the current Covered Code List, reference the Medicare Claims Processing Manual, Chapter 120 (Clinical Laboratory Services Based on Negotiated Rulemaking), linked from the NCD 46 policy page at CMS.gov.
| Code | Type | Notes |
|---|---|---|
| See CMS Quarterly Covered Code Lists | CPT/HCPCS | Published quarterly; check CMS Regulations and Guidance for current list |
What This Means for Your Charge Capture
The absence of codes in the policy body is not unusual for laboratory NCDs — CMS maintains the code lists separately to allow updates without triggering a full NCD revision cycle. But it does mean your billing team needs a process to check those quarterly updates. If you're not monitoring the Covered Code Lists, you may be billing codes that have been added, removed, or modified without realizing it.
If your revenue cycle team needs help confirming which codes map to HIV plasma RNA quantification under current CMS billing guidelines, loop in your billing consultant or verify directly against the current quarterly list before submitting claims after January 9, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.